SOM230 Ectopic ACTH-producing Tumors

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this prospective open-label phase II study, is to evaluate the efficacy of pasireotide twice daily subcutaneous injections for normalizing 24 hour urine free cortisol in patients with ectopic ACTH-producing tumors as measured by the proportion of patients achieving normal UFC at the end of the study period.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00958841` - Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin	Phase 2
	Recruiting	`NCT05804669` - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome	Phase 1/Phase 2

NCT number	NCT02780882
Study type	Interventional
Source	Cedars-Sinai Medical Center
Contact
Status	Withdrawn
Phase	Phase 2
Start date	December 2015
Completion date	June 2019

SOM230 Ectopic ACTH-producing Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms